The global olanzapine market is anticipated to grow at a CAGR of around 2.8% during the forecast period 2020 to 2027 and to reach around US$ 237.9 Mn by 2027.
Market Dynamics
Noticeable increase in number of inpatients in hospitals suffering from diseases such as schizophrenia and bipolar disorder coupled with increasing focus on R&D activities by major players for development of novel medication are major factors expected to drive the growth of global market. According to Depression and Bipolar Support Alliance, bipolar disorder affects approximately 5.7 million adult Americans, or about 2.6% of the U.S. population age 18 and older every year. Bipolar disorder is more likely to affect the children of parents who have the disorder. When one parent has bipolar disorder, the risk to each child is 15% to 30%. When both parents have bipolar disorder, the risk increases to 50% to 75%.
In addition, high investment by major players for R&D activities and approach towards collaborative work for development of innovative products in order to attract new customers are factors expected to support the growth of target market.
In 2020, Indoco Remedies Ltd. a pharmaceutical manufacturer received approval for its ANDA for Olanzapine tablets USP 2.5mg, 5mg, 7.5 mg, 10mg, 15mg and 20 mg. This is expected to help the company to sell the product and enhance the revenue.
In 2020, Alkermes plc a pharmaceutical manufacturing and biopharmaceutical company developing innovative medicines has received approval of ALKS 3831 (olanzapine/samidorphan) for the treatment of schizophrenia and for the treatment of bipolar disorder from the FDA. This is expected to help the company to enhance the business presence and increase the revenue share.
In 2019, Intra-Cellular Therapies, Inc. a biopharmaceutical company received approval from FDA for Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults. This is expected to help the company to enhance the business presence and enhance the product portfolio.
However, factors such as high cost of R&D and strict government regulations related to product approval are factors expected to hamper the growth of global olanzapine market. In addition, side effects of the medication such as drowsiness, dizziness, lightheadedness, etc. is expected to challenge the growth of target market.
High investment by the players and collaborative work between private-public players are factors expected to create new opportunities for players operating in the target market over the forecast period. In addition, increasing partnership between international and regional players is expected to support the revenue transaction of target market.
Segment Analysis by Region
The market in North America is expected to account for major revenue share in the target market due to high patient pool suffering from chronic disease. In addition, government focus on development of smart healthcare system along with player’s inclination towards enhancing the patient care are factors expected to support the growth of target market.
Increasing acquisition and partnership activities by major players in order to increase the company presence and enhance the customer base are factors expected to support the growth of target market.
Competitive Landscape
The global market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Report coverage
Market |
Global Olanzapine Market |
Analysis Period |
2016 – 2027 |
Base Year |
2019 |
Forecast Data |
2020 – 2027 |
Market Stratification |
Type, Application and Geography |
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa |
Report Coverage |
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis |
Olanzapine Market Segment Analysis, 2019
The global market is segmented into type and application. The type segment is bifurcated into patent type and generics type. Among the type segment the patient type segment is expected to account for major revenue share in the target segment. The application segment is divided into olanzapine tablets and other medicine. Among the application the olanzapine tablets segment is expected to account for significant revenue share in the target market.
The players profiled in the report are Zhejiang Langhua Pharmaceuticals, Hansoh Pharmaceutical, Aurobindo Pharma, Jubilant Lifesciencest, Torrent Pharmaceuticals, Sun Pharmaceutical, Eli Lilly and Company, WATSON Pharmaceuticals, Hanson Pharmaceutical, Sandoz, Dr. Reddy’s Laboratories, Mylan Pharmaceuticals,Apotex Inc.,Teva Pharmaceutical.
Market Segmentation
Market By Type
Patent Type
Generics Type
Market By Application
Olanzapine Tablets
Other Medicine
Market By Region
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
Noticeable increase in number of inpatients in hospitals suffering from diseases such as schizophrenia and bipolar disorder coupled with increasing focus on R&D activities by major players for development of novel medication are major factors expected to drive the growth of global market.
The global olanzapine market in 2027 is expected to be above US$ 237.9 Mn.
In application the olanzapine tablets segment is growing at faster pace.
The CAGR of the global olanzapine market from 2020-2027 is above 2.8%.
In the global market the Asia Pacific region is expected to grow faster.
Some of the players considered in the report scope are Zhejiang Langhua Pharmaceuticals, Hansoh Pharmaceutical, Aurobindo Pharma, and Jubilant Life sciences.
The Asia Pacific is expected to account for major revenue share in the global market.